G-BA decisions from 17 October 2024
Here are the latest G-BA decisions from the G-BA meeting held on 17 Oct 2024 on the early benefit assessments of Spexotras,
Category: Uncategorized
Insights on Germany’s Market Access – Interview with Market Access Today
In May 2024, I had the pleasure of being interviewed by Oznur Seyhun from Market Access Today.
G-BA implements another reimbursement restriction – Febuxostat in hyperuricemia
Most medicines are reimbursed at 100% from the day of launch in Germany, i.e. coverage by SHI funds is granted with the marketing authorization
G-BA criticises submitted data for assessments of pralsetinib and idecabtagen vicleucel
On 16 June 2022, the G-BA published its findings on the benefit assessments of Gavreto (pralsetinib) and Abecma (idecabtagen vicleucel). Both drugs
Happy Holidays!
Here is my last blog post of the year. Somehow we’ve come to the end of another year. Most of us are